( Patients and physicians should find th...)Interim Data From RECORD Study Show No Significant Difference,Between Avandia and Standard Therapy in Risk of Cardiovascular,Hospitalization or Death,Health

PHILADELPHIA, June 05, 2007 /PRNewswire-FirstCall/ -- GlaxoSmithKline said today that findings from an interim analysis of RECORD (Rosiglitazone Evaluated for Cardiac Outcomes and Regulation of glycemia in Diabetes), a prospective clinical trial designed specifically to determine cardiovascular outcomes in more than 4,400 patients with type 2 diabetes, adds further evidence to the overall cardiovascular safety profile of Avandia(R) (rosiglitazone maleate). The study results, authored by Philip D. Home and colleagues on the RECORD Steering Committee, were published Tuesday in the online edition of The New England Journal of Medicine.

The study compares cardiovascular hospitalization and death in patients treated with Avandia dual therapy (Avandia plus metformin or sulfonylurea) and in patients treated with metformin and sulfonylurea in combination. After following patients for an average of 3.75 years, the interim analysis found a low number of events overall, and a similar number of events in each group. The study is scheduled to complete in late 2008.

Like all interim analyses, these data do not offer final conclusions. Based on the interim analysis, key findings include:

    -- The interim data show no significant difference between the Avandia and

       control groups in the key outcomes of hospitalization or death due to

       cardiovascular events.

    -- There was no difference between the groups in mortality, whether

       cardiovascular deaths or deaths from all causes.

    -- The interim data show that Avandia was not significantly different than

       the control groups in several secondary outcomes, including heart

       attack.

    -- A significant difference between the Avandia and control groups was

       seen only in the secondary outcome of congestive heart failure (CHF),

       where significantl
'"/>




Page: 1 2 3 4 5 
Related medicine technology :

1. Cell Therapeutics, Inc. Management to Discuss Todays Announcement
of Interim Pixantrone Study Results
2. Positive ZIO-201 Interim Phase II Sarcoma Data Presented at
European Society for Medical Oncology
3. Ablynx Announces Interim Results of First Nanobody Phase I Study of
ALX-0081 (ANTI-VWF)
4. Based on Up to 6 Years of Follow-Up, Biovest Announces Favorable
Interim Blinded Data for Fast-Tracked Pivotal Phase 3 Clinical
Trial of BiovaxID Anti-Cancer Vaccine for Non-Hodgkins Lymphoma
5. ZIO-101 (Darinaparsin) Interim Phase II and Preclinical Data
Presented at International Myeloma Workshop
6. Accentia Biopharmaceuticals Announces Favorable Interim Blinded
Data on SinuNase in Its Fast-Tracked Pivotal Phase 3 Clinical Trial
for Chronic Sinusitis
7. Pharmacyclics Announces Interim Results From Two Ongoing Phase 2
Trials Supporting Potential of Xcytrin Plus Chemotherapy to Treat
Recurrent Non-Small Cell Lung Cancer
8. Interim Analysis of Crinone Pregnancy Study to Be Published in
American Society for Reproductive Medicine Journal
9. Avalon Pharmaceuticals Announces Positive Interim Results For
AVN944 Phase I Trial
10. Vical Interim Clinical Results Demonstrate Safety and Tolerability
of Inovio Biomedicals Electroporation DNA Delivery Technology
11. Gloucester Pharmaceuticals Reports Positive Interim Phase II Data
on Romidepsin for T-Cell Lymphomas at the 2007 American Society of
Clinical Oncology Annual Meeting